Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Choosing wisely in complementary treatment for cancer in the Philippines

Dr Ann Meredith Garcia-Trinidad - Dagupan Doctors Villaflor Memorial Hospital, Dagupan City, Philippines
Choosing wisely in complementary treatment for cancer in the Philippines ( Dr Ann Meredith Garcia-Trinidad - Dagupan Doctors Villaflor Memorial Hospital, Dagupan City, Philippines )
19 Apr 2023

Indications for the appropriate use of a PET-CT scan for common cancers

Dr Jonas Santiago - St Luke's Medical Center, Manila, Philippines
Indications for the appropriate use of a PET-CT scan for common cancers ( Dr Jonas Santiago - St Luke's Medical Center, Manila, Philippines )
19 Apr 2023

Choosing Wisely in neoadjuvant treatment for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines
Choosing Wisely in neoadjuvant treatment for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )
19 Apr 2023

Current indications and challenges with IORT in the Philippines

Dr Henri Cartier Co - Philippine General Hospital, Manila, Philippines
Current indications and challenges with IORT in the Philippines ( Dr Henri Cartier Co - Philippine General Hospital, Manila, Philippines )
12 Apr 2023

A multidisciplinary team approach to cancer care in the Philippines

Dr Arnold John Uson - Perpetual Succour Hospital of Cebu, Cebu, Philippines
A multidisciplinary team approach to cancer care in the Philippines ( Dr Arnold John Uson - Perpetual Succour Hospital of Cebu, Cebu, Philippines )
12 Apr 2023

Choosing the right serum and molecular biomarkers in the Philippines

Dr Jose Jasper Andal - St Luke's Medical Center, Manila, Philippines
Choosing the right serum and molecular biomarkers in the Philippines ( Dr Jose Jasper Andal - St Luke's Medical Center, Manila, Philippines )
12 Apr 2023

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
11 Apr 2023

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
11 Apr 2023

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )
6 Apr 2023

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC

Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC ( Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )
5 Apr 2023